肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

阿斯利康的Imfinzi无法提高头颈癌患者的总体生存率

2021-02-09 Allan MedSci原创

Tremelimumab头颈癌Imfinzi（durvalumab）
关注

阿斯利康的Imfinzi在第二次试验中仍未能改善复发或转移性头颈部鳞状细胞癌（HNSCC）患者的总体生存期（OS）。

阿斯利康的Imfinzi在第二次试验中仍未能改善复发或转移性头颈部鳞状细胞癌（HNSCC）患者的总体生存期（OS）。对Imfinzi（durvalumab）的KESTREL III期临床试验的更新发现，在表达高水平PD-L1的HNSCC患者中，与化疗联合西妥昔单抗治疗方案相比，Imfinzi（durvalumab）无法改善OS。Imfinzi联合CTLA-4靶向抗体tremelimumab的组合也未能改善患者的OS。

阿斯利康肿瘤学业务部门执行副总裁Dave Fredrickson说：“转移性头颈癌是一种复杂且具有挑战性的疾病，患者预后很差。尽管我们对这些结果感到失望，但来自KESTREL III期试验的经验将促进我们对免疫疗法的理解”。

此前，Imfinzi在2018年的EAGLE III期试验中也未能在HNSCC患者中显示出益处。EAGLE III期试验评估了Imfinzi单药疗法或Imfinzi联合tremelimumab治疗铂类化疗后疾病进展的复发或转移性头颈鳞状细胞癌（HNSCC）患者，结果显示，与标准化疗（SoC）相比，不论患者PD-L1水平如何，Imfinzi单药疗法以及Imfinzi与tremelimumab的联合治疗均不能改善患者OS。

 

原始出处：

http://www.pharmatimes.com/news/azs_imfinzi_fails_to_improve_overall_survival_in_head_and_neck_cancer_again_1362889

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668529, encodeId=9d4f16685294c, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52745, encryptionId=2df452e4557, topicName=总体生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf0826335696, createdName=般若傻瓜, createdTime=Mon Nov 08 16:14:26 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256811, encodeId=a62d12568116e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295911, encodeId=ce61129591126, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416499, encodeId=e1d41416499dc, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=)]
    2021-11-08 般若傻瓜

    #总体生存率#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1668529, encodeId=9d4f16685294c, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52745, encryptionId=2df452e4557, topicName=总体生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf0826335696, createdName=般若傻瓜, createdTime=Mon Nov 08 16:14:26 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256811, encodeId=a62d12568116e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295911, encodeId=ce61129591126, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416499, encodeId=e1d41416499dc, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=)]
    2021-02-11 guoyibin

    #生存率#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1668529, encodeId=9d4f16685294c, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52745, encryptionId=2df452e4557, topicName=总体生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf0826335696, createdName=般若傻瓜, createdTime=Mon Nov 08 16:14:26 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256811, encodeId=a62d12568116e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295911, encodeId=ce61129591126, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416499, encodeId=e1d41416499dc, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=)]
    2021-02-11 DEXTER3139

    #头颈癌#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1668529, encodeId=9d4f16685294c, content=<a href='/topic/show?id=2df452e4557' target=_blank style='color:#2F92EE;'>#总体生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52745, encryptionId=2df452e4557, topicName=总体生存率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf0826335696, createdName=般若傻瓜, createdTime=Mon Nov 08 16:14:26 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256811, encodeId=a62d12568116e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295911, encodeId=ce61129591126, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416499, encodeId=e1d41416499dc, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Thu Feb 11 08:14:26 CST 2021, time=2021-02-11, status=1, ipAttribution=)]
    2021-02-11 swallow

    #Imfinzi#

    0

相关资讯

MYSTIC研究：durvalumab与tremelimumab联用无法显著提高肺癌患者的生存率

阿斯利康近日宣布，在III期MYSTIC研究中，与标准铂类化疗相比，PD-L1抑制剂Imfinzi（durvalumab）作为单药疗法及与抗CTLA4抗体tremelimumab的联合使用未能显著提高初治IV期非小细胞肺癌（NSCLC）患者的总生存期（OS）。

durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗

阿斯利康近日宣布，与标准铂类化疗相比，Imfinzi（durvalumab）联合使用tremelimumab治疗初治IV期非小细胞肺癌（NSCLC）患者的III期NEPTUNE研究未能达到总生存期（OS）的主要终点。

Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效

在错配修复熟练(MMR-P)的转移性结直肠癌(mCRC)中，单用免疫检查点抑制剂(ICI)并不能获得预期疗效，单用放疗(RT)也不能带来客观的全身益处，两者联用是否会带来不一样的结局呢？

Lancet respir med：Tremelimumab（抗CTLA4单克隆抗体）联合durvalumab（抗PD-L1单克隆抗体）用于间皮瘤的疗效和安全性

Tremelimumab，抗CTLA4单克隆抗体，最初单独用于间皮瘤患者活性良好，但不能提高DETERMINE研究中一线或二线化疗失败的患者的总体存活率（与安慰剂对比）。现研究人员对Tremelimumab联合durvalumab（抗PD-L1单克隆抗体），作为一线或二线疗法，用于恶性间皮瘤的疗效和安全性进行评估。研究人员开展一开放性、非随机的临床II期试验，招募不可手术切除的胸膜或腹膜间皮瘤，予

J Hepatol：Tremelimumab治疗晚期肝癌的可行性研究

Tremelimumab是一个完全的人类单克隆抗体,结合于活化的T淋巴细胞表面的CTLA-4。消融疗法已被证明可以诱导外周免疫反应，从而增强抗CTLA4治疗晚期HCC患者的疗效。 纳入HCC患者（Childs Pugh A/B7;巴塞罗那临床肝癌分期B/C; ECOG 0/1）。结合消融疗法使用tremelimumab治疗。在基线和放射学介入时，进行肿瘤活检。 研究纳入了32例患者，男

拓展阅读

JHO：记忆样NK细胞联合IL-15超激动剂及CTLA-4阻断在晚期头颈癌治疗中的初步结果

本研究为NK细胞治疗领域提供了重要的临床第一手资料，尤其是在固体肿瘤如头颈癌中的应用探索具有开创意义。

适当喝茶和咖啡，或有助于防癌！新研究提示，脱咖啡因咖啡同样有效

近日，Cancer发表一项研究结果表明，饮用咖啡和茶或有助于降低头颈癌的发生风险。

绘真约大咖 | 余德教授：复发/转移性头颈癌患者精准治疗应关注哪些基因检测？

本期的【绘真有约·大咖答疑】非常荣幸邀请到了厦门大学附属中山医院——余德教授，针对上述问题做了简要解答。

I期临床表明：iNKT细胞疗法使头颈癌患者肿瘤直径缩减近50%，且耐受性良好！

头颈癌，是头部或颈部异常细胞以不受控制方式生长时发生的恶性肿瘤，通常始于口腔、鼻子和喉咙内部的鳞状细胞。

【今日分享】2024 国际指南：肿瘤内和结内注射NBTXR3纳米颗粒在头颈癌中的作用

本文主要介绍了口腔、口咽部和颈部淋巴结头颈部鳞状细胞癌（HNSCC）肿瘤内和结内注射NBTXR3氧化铪纳米粒子的最佳方法。点击立即下载查看。

领跑肿瘤新前沿|一周热点大分享！

肿瘤学热点一网打尽！深入解读权威指南，分享最受欢迎的治疗公式，为您的临床决策提供有力支持。不容错过的肿瘤治疗新知识，尽在这理，点击立即查看！